High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 3, 2008, Pages 429-436

  Urbich, Carmen ^a   Dernbach, Elisabeth ^a   Rössig, Lothar ^a   Zeiher, Andreas M ^a   Dimmeler, Stefanie ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cathepsins; Diabetes mellitus; Glucose; Progenitor cells; Proteases

Indexed keywords

CATHEPSIN D; CATHEPSIN L; CATHEPSIN O; GELATINASE A; GELATINASE B; GLUCOSE; MESSENGER RNA; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; ARTICLE; CELL INVASION; CELL REGENERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEGRADATION; DIABETES MELLITUS; DOWN REGULATION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; STEM CELL; TRANSCRIPTION REGULATION;

ADULT; AGED; CATHEPSINS; CELL MOVEMENT; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS;

EID: 50449084774     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.06.004     Document Type: Article

References (53)

1. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
2. Isner J.M., and Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103 (1999) 1231-1236
3. Kalka C., Masuda H., Takahashi T., Kalka-Moll W.M., Silver M., Kearney M., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3422-3427
4. Murohara T., Ikeda H., Duan J., Shintani S., Sasaki K., Eguchi H., et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 105 (2000) 1527-1536
5. Urbich C., Heeschen C., Aicher A., Dernbach E., Zeiher A.M., and Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108 (2003) 2511-2516
6. Kaushal S., Amiel G.E., Guleserian K.J., Shapira O.M., Perry T., Sutherland F.W., et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat. Med. 7 (2001) 1035-1040
7. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95 (2000) 952-958
8. Shi Q., Rafii S., Wu M.H., Wijelath E.S., Yu C., Ishida A., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92 (1998) 362-367
9. Walter D.H., Rittig K., Bahlmann F.H., Kirchmair R., Silver M., Murayama T., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 (2002) 3017-3024
10. Werner N., Priller J., Laufs U., Endres M., Bohm M., Dirnagl U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb. Vasc. Biol. 22 (2002) 1567-1572
11. Hur J., Yoon C.H., Kim H.S., Choi J.H., Kang H.J., Hwang K.K., et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb. Vasc. Biol. 24 (2004) 288-293
12. Kawamoto A., Gwon H.C., Iwaguro H., Yamaguchi J.I., Uchida S., Masuda H., et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103 (2001) 634-637
13. Kocher A.A., Schuster M.D., Szabolcs M.J., Takuma S., Burkhoff D., Wang J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7 (2001) 430-436
14. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360 (2002) 427-435
15. Assmus B., Schachinger V., Teupe C., Britten M., Lehmann R., Dobert N., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106 (2002) 3009-3017
16. Schachinger V., Assmus B., Honold J., Lehmann R., Hofmann W.K., Martin H., et al. Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin. Res. Cardiol. 95 (2006) 13-22
17. Schachinger V., Erbs S., Elsasser A., Haberbosch W., Hambrecht R., Holschermann H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355 (2006) 1210-1221
18. Assmus B., Honold J., Schachinger V., Britten M.B., Fischer-Rasokat U., Lehmann R., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 355 (2006) 1222-1232
19. Rehman J., Li J., Orschell C.M., and March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107 (2003) 1164-1169
20. Urbich C., Aicher A., Heeschen C., Dernbach E., Hofmann W.K., Zeiher A.M., et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39 (2005) 733-742
21. Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89 (2001) E1-E7
22. Walter D.H., Haendeler J., Reinhold J., Rochwalsky U., Seeger F., Honold J., et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ. Res. 97 (2005) 1142-1151
23. Schatteman G.C., Hanlon H.D., Jiao C., Dodds S.G., and Christy B.A. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J. Clin. Invest. 106 (2000) 571-578
24. Loomans C.J., de Koning E.J., Staal F.J., Rookmaaker M.B., Verseyden C., de Boer H.C., et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53 (2004) 195-199
25. Tepper O.M., Galiano R.D., Capla J.M., Kalka C., Gagne P.J., Jacobowitz G.R., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106 (2002) 2781-2786
26. Ii M., Takenaka H., Asai J., Ibusuki K., Mizukami Y., Maruyama K., et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ. Res. 98 (2006) 697-704
27. van Hinsbergh V.W., Engelse M.A., and Quax P.H. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb. Vasc. Biol. 26 (2006) 716-728
28. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 9 (2005) 267-285
29. Urbich C., Heeschen C., Aicher A., Sasaki K., Bruhl T., Farhadi M.R., et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat. Med. 11 (2005) 206-213
30. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108 (2001) 391-397
31. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9 (2003) 1370-1376
32. Dennhofer R., Kurschat P., Zigrino P., Klose A., Bosserhoff A., van Muijen G., et al. Invasion of melanoma cells into dermal connective tissue in vitro: evidence for an important role of cysteine proteases. Int. J. Cancer 106 (2003) 316-323
33. Felbor U., Dreier L., Bryant R.A., Ploegh H.L., Olsen B.R., and Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. Embo J. 19 (2000) 1187-1194
34. Fiebiger E., Maehr R., Villadangos J., Weber E., Erickson A., Bikoff E., et al. Invariant chain controls the activity of extracellular cathepsin L. J. Exp. Med. 196 (2002) 1263-1269
35. Callaghan M.J., Ceradini D.J., and Gurtner G.C. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid. Redox. Signal 7 (2005) 1476-1482
36. Loomans C.J., De Koning E.J., Staal F.J., Rabelink T.J., and Zonneveld A.J. Endothelial progenitor cell dysfunction in type 1 diabetes: another consequence of oxidative stress?. Antioxid Redox Signal 7 (2005) 1468-1475
37. Dernbach E., Urbich C., Brandes R.P., Hofmann W.K., Zeiher A.M., and Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood 104 (2004) 3591-3597
38. He T., Peterson T.E., Holmuhamedov E.L., Terzic A., Caplice N.M., Oberley L.W., et al. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2021-2027
39. Wilson N.L., Schulz B.L., Karlsson N.G., and Packer N.H. Sequential analysis of N- and O-linked glycosylation of 2D-PAGE separated glycoproteins. J. Proteome Res. 1 (2002) 521-529
40. Luhr K.M., Nordstrom E.K., Low P., and Kristensson K. Cathepsin B and L are involved in degradation of prions in GT1-1 neuronal cells. Neuroreport 15 (2004) 1663-1667
41. Nakanishi H., Tominaga K., Amano T., Hirotsu I., Inoue T., and Yamamoto K. Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues. Exp. Neurol. 126 (1994) 119-128
42. Pistrosch F., Herbrig K., Oelschlaegel U., Richter S., Passauer J., Fischer S., et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183 (2005) 163-167
43. Gensch C., Clever Y.P., Werner C., Hanhoun M., Bohm M., and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192 (2007) 67-74
44. Wang C.H., Ting M.K., Verma S., Kuo L.T., Yang N.I., Hsieh I.C., et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J. 152 1051 (2006) e1-e8
45. Humpert P.M., Djuric Z., Zeuge U., Oikonomou D., Seregin Y., Laine K., et al. Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor dependent signalling. Mol. Med. 14 (2008) 301-308
46. Death A.K., Fisher E.J., McGrath K.C., and Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168 (2003) 263-269
47. Uemura S., Matsushita H., Li W., Glassford A.J., Asagami T., Lee K.H., et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ. Res. 88 (2001) 1291-1298
48. Krankel N., Adams V., Linke A., Gielen S., Erbs S., Lenk K., et al. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb. Vasc. Biol. 25 (2005) 698-703
49. Seeger F.H., Haendeler J., Walter D.H., Rochwalsky U., Reinhold J., Urbich C., et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 111 (2005) 1184-1191
50. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad Sci. U. S. A. 87 (1990) 6624-6628
51. Lawler J. The functions of thrombospondin-1 and -2. Curr. Opin. Cell. Biol. 12 (2000) 634-640
52. Hogg P.J., Owensby D.A., and Chesterman C.N. Thrombospondin 1 is a tight-binding competitive inhibitor of neutrophil cathepsin G. Determination of the kinetic mechanism of inhibition and localization of cathepsin G binding to the thrombospondin 1 type 3 repeats. J. Biol. Chem. 268 (1993) 21811-21818
53. Rabhi-Sabile S., Pidard D., Lawler J., Renesto P., Chignard M., and Legrand C. Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. FEBS Lett. 386 (1996) 82-86